Angela Thedinga, MBA, MPH
Angela Thedinga, MBA, MPH was appointed chief technology officer in February 2020. She joined Adverum in August 2019 as vice president, program management. Prior to joining Adverum, Ms. Thedinga served as vice president of program management and chief of staff at AveXis, Inc., a gene therapy company acquired by Novartis in 2018. Ms. Thedinga was instrumental in developing the early manufacturing strategy which enabled AveXis to transition its early-stage AAV manufacturing process to a scalable commercial manufacturing process. As chief of staff at AveXis, Ms. Thedinga led the company-wide effort for the global simultaneous regulatory submissions and the commercial launch of Zolgensma®, the first systemically delivered AAV gene therapy to receive approval by the U.S. Food and Drug Administration. Ms. Thedinga earned a Master’s degree in chemical engineering from the Massachusetts Institute of Technology (MIT), a Master of Business Administration from the MIT Sloan School of Management, a Master of Public Health from the University of North Carolina at Chapel Hill, and a Bachelor of Science in chemical engineering from the University of Wisconsin.